Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival (Q34310131)

1 August 2017

Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival (English)

1 reference

1 August 2017

1 reference

1 reference

1

Robert C G Martin

1 reference

1 August 2017

Kelli McFarland

2

1 reference

1 August 2017

Susan Ellis

series ordinal

3

1 reference

1 August 2017

Vic Velanovich

series ordinal

4

1 reference

1 August 2017

6 November 2012

1 reference

Annals of Surgical Oncology

1 August 2017

1 reference

1 August 2017

20 Suppl 3

1 reference

1 August 2017

S443-9

1 reference

https://scigraph.springernature.com/pub.10.1245/s10434-012-2736-1

1 August 2017

0 references

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2736-1

Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2736-1

Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2736-1

Tumor ablation with irreversible electroporation

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2736-1

In vivo results of a new focal tissue ablation technique: irreversible electroporation

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2736-1

Tissue ablation with irreversible electroporation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2736-1

Electrical impedance tomography for imaging tissue electroporation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2736-1

Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2736-1

Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2736-1

Arterial and venous resection for pancreatic adenocarcinoma: operative and long-term outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2736-1

Resection of the celiac axis for invasive pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2736-1

Irreversible electroporation of the pancreas: definitive local therapy without systemic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2736-1

DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2736-1

Irreversible electroporation of the pancreas in swine: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2736-1

10.1245/S10434-012-2736-1

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

1 August 2017

0 references

1 reference